Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2XSJCZR
via IFTTT